Strategic Partnerships SiSaf is actively expanding its Bio-Courier platform through collaborations with universities and research organizations (e.g., University of Leipzig, Thescientificreporters, Gala Dinner). This presents opportunities to position as a preferred partner for co-development, translational research, and joint grant-funded programs in RNA delivery and miRNA therapeutics.

AI and Governance Recent leadership additions include a Chief AI Officer and a Board of Directors appointment, signaling a push toward advanced analytics, data-driven optimization, and robust governance. This creates entry points to offer AI-augmented R&D services, data management solutions, and strategic advisory partnerships.

Early-Stage Pipeline With a focus on rare genetic disorders and cancer via Bio-Courier targeted miRNA and sshLNP technologies, SiSaf represents a growing customer base for CRO/CDMO services, contract research, and licensing discussions for preclinical to early clinical programs.

Funding Readiness Backed by VC funding and a revenue profile under one million with a $29M funding runway, SiSaf may be seeking strategic investments, technology licensing deals, or collaboration agreements to de-risk and scale their pipeline, making them receptive to partnerships and pilot programs.

Global Collaborations Active international partnerships and press coverage indicate openness to global collaborations. This opens sales avenues for joint development agreements, technology licensing, and access to international translational resources, markets, and distribution networks.